Kathryn A. Lyons

Statistics

Publications

Citations

3.9K

H-Index

Active since

1983

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

CHDI Foundation

Kathryn A. Lyons is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and drug discovery.

Publications per year

1983–2018

Publications

(2R)-4-Oxo-4-[3-(Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Dooseop Kim, Liping Wang, Maria Beconi et al. · Journal of Medicinal Chemistry · 2004 · 817 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes

George R. Lankas, Barbara Leiting, Ranabir Sinha Roy et al. · Diabetes · 2005 · 491 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Timing and Relative Intensity of Hip Extensor and Abductor Muscle Action During Level and Stair Ambulation

Kathryn A. Lyons, Jacquelin Perry, JoAnne K. Gronley et al. · Physical Therapy · 1983 · 270 citations

Education, Anatomy, Physiology +17

The role of working memory in decoding emotions.

Shelley Channon, Mary Tunstall, Anna Hedenstrom et al. · Emotion · 2008 · 125 citations

Social Sciences, Neuroscience, Psychology +17

(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]- pyridin-6-ylphenyl)butanamide: A Selective α-Amino Amide Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes

Scott D. Edmondson, Anthony Mastracchio, Robert J. Mathvink et al. · Journal of Medicinal Chemistry · 2006 · 121 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16

1–5 of 59